Radiation and Prostate Cancer Past, Present and Future Dr

Slides:



Advertisements
Similar presentations
Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.
Advertisements

US TOO INTERNATIONAL, INC US TOO GREATER QUAD CITIES PROSTATE CANCER SUPPORT GROUP.
10th Annual Lung Cancer Conference Radiation Oncology
Carcinoma of the Prostate By: Ishan Parikh. Background on Cancer  Oldest information dates back to 3000 BC, Egyptian textbook on trauma surgery – “There.
Advances in Early Diagnosis and Treatment of Cancer July 17, 2007.
Targeting Issues For Proton Treatments Of The Prostate SJ Rosenthal Ph.D., JA Wolfgang Ph.D., Sashi Kollipara Department of Radiation Oncology Massachusetts.
Stereotactic Radiosurgery Jimmy Johannes Physics 335 – Spring 2004 Final Presentation
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
Introduction to Radiation Therapy
Radiation Protection in Radiotherapy
Radiotherapy for Brain Tumours What do I need to know? Dr Matthew Foote Radiation Oncologist Princess Alexandra Hospital Queensland.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.
By Denae Bush.   1.The disease caused by an uncontrolled division of abnormal cells in a part of the body.  2.A malignant growth or tumor resulting.
NEW OPTIONS IN PROSTATE CANCER TREATMENT Presented by Triangle Urology Associates, P.A.
Prostate Cancer Treatments By: Ishan Parikh. Symptoms Be on the look out for… “stop-and-go” flow of urine Sudden urges to urinate Frequent urination (esp.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
Objectives: Our first segment focused in the anatomy and functions of the prostate gland, to get a clear understanding of the male Genito-Urinary System.
Radiotherapy Planning for Esophageal Cancers Parag Sanghvi, MD, MSPH 9/12/07 Esophageal Cancer Tumor Board Part 1.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Radiotherapy for Kidney cancer
Ch .4 Clinical Radiation Generators
Simulating Potential Layouts for a Proton Therapy Treatment Center Stuart Price-University of Maryland Bruce Golden- University of Maryland Edward Wasil-
Time, Dose, and Fractionation
Radiotherapy - the art of the invisible Terry Kehoe Consultant Clinical Scientist Head of Oncology Physics Edinburgh Cancer Centre “How to crack a walnut”
 The CyberKnife is a type radiation emitting machine used for the treatment of cancer. It emits radiation in high doses to millimeter precision. The.
Comparison of Rectal Dose Volume Histograms for Definitive Prostate Radiotherapy Among Stereotactic Radiotherapy, IMRT, and 3D-CRT Techniques Author(s):
Prostate Cancer By: Kurt Rishel.
Mark L. Merlin, M.D. Radiotherapy Clinics of Georgia 7/14/2010 The Role of Radiation Therapy in the Management of Prostate Cancer.
Prostate Support Group Dr Duncan McLaren Consultant Oncologist.
Using Radiation in Medicine. There are 3 main uses of radiation in medicine: Treatment Diagnosis Sterilization.
PROSTATE CANCER: RADIATION THERAPY APPROACHES ANDREW L. SALNER, MD FACR DIRECTOR HELEN & HARRY GRAY CANCER CENTER HARTFORD HOSPITAL, CT.
Cell Division Gone Wrong….
1 Prostate Cancer. 2 Prostate Gland Muscular Walnut-sized gland Makes seminal fluid Muscles contract to push semen through the urethra Located directly.
Introduction to Radiation Therapy
Optimization of Volumetric Modulated Arc Therapy (VMAT) Planning Strategy Using Ring-shaped ROI for Localized Prostate cancer Kentaro Ishii, Masako Hosono,
Understanding Prostate Myths
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized Prostate Cancer David M. Spellberg M.D., FACS Naples Urology Associates,
Understanding Radiation Therapy
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.
HIFU AND CRYOSURGERY David Spellberg M.D., FACS.
Stereotactic Body Radiation Therapy for Early Stage Prostate Cancer: Outcomes from a Single Institution Study Stereotactic Body Radiation Therapy for Early.
Carcinoma of the prostate. INTRODUCTION Prostate cancer is the most common cancer diagnosed and is the second leading cause of cancer death in men in.
Cancer What is cancer? uncontrolled cell growth that leads to the formation of primary tumors cells that spread (metastasize) to other areas of the body.
Statistics (from the National Institutes of Health) on average, in the US, people have a 2 in 5 lifetime risk of developing cancer second leading cause.
Dose Calculations for Cyberknife Stereotactic Body Radiation Therapy For CK, one can fractionate the therapy yet remain convenient and non-invasive for.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized and Advanced Prostate Cancer David M. Spellberg M.D., FACS Naples.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized Prostate Cancer David M. Spellberg M.D., FACS.
Lung SBRT Implementation at the Regional Cancer Centre
Understanding Radiation Therapy Lecturer Radiological Science
Modern Radiation Oncology
Radiation therapy for Early Stage Prostate Cancer
Kasey Etreni BSc., MRT(T), RTT, CTIC
Extending intracranial treatment options with Leksell Gamma Knife® Icon™ Key Statements from Customer Perspective by University Medical Centre Mannheim.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.
Colorectal SSG: SABR and Oligometastatic Disease
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized and Advanced Prostate Cancer David M. Spellberg M.D., FACS Naples.
RTOG 0126 A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Bijoy.
أجهزة العلاج الإشعاعي Clinical Radiation Generator
Prostate Cancer: Highlights from 2006
Insert tables Insert figure
Volumetric Modulated Arc Therapy (VMAT) versus Intensity Modulated Radiation Therapy (IMRT) for Anal Carcinoma Heather Ortega, BSRT(T), CMD, Kerry Hibbitts,
Dosimetry of Alternative Techniques for Accelerated Partial Breast Irradiation Hanh Pham, B.S, CMD, Thanh Nguyen, BS, Christina Henson, MD, Salahuddin.
Radiation Therapy for Prostate Cancer
Clinical Radiation Oncology NMT232 L 10
Chapter 17 Intensity-Modulated Radiation Therapy
CANCER Detection and Treatment
Principles of Radiation Therapy
Presentation transcript:

Radiation and Prostate Cancer Past, Present and Future Dr Radiation and Prostate Cancer Past, Present and Future Dr. Tom Corbett MD FRCPC Juravinski Cancer Centre

We’ve come a long way! Not all prostate cancers are the same. Nor are all men the same (different priorities).

Goals Review the basics of prostate cancer Review a brief history of radiation therapy Discuss the new advances in radiation treatment as they apply to prostate cancer

Prostate Cancer The Basics

Prognostic Factors PSA Gleason Score T Stage

Prostate Specific Antigen PSA Prostate Specific Antigen Normal value is <4 ng/ml, but varies with age, size of prostate, benign prostatic changes (inflammation) Higher values usually indicate a greater amount of cancer. PSA versus free-PSA

Gleason Score A description by the pathologist of how the cancer looks under the microscope. Scores range from 2 to 10. Scores of 2-6 are generally slow growing. Scores of 7 are average. Scores of 8 to10 are more aggressive.

T stage Refers to how the prostate feels on “the finger check” or DRE (digital rectal examination)

Risk Categories Low Risk All of: ≤ T2a PSA ≤10 Gleason ≤ 6 Intermediate Risk ≥ T2b PSA ≤ 20 Gleason ≤ 7 High Risk Any ≥ T3a PSA >20 Gleason ≥ 8

Brief History of Radiation X-rays First found in 1875 First studied in 1895 First used to treat cancer 1896

Early X-Ray Treatment Limited by energy (20 – 150 kV) Treatments limited to superficial structures (not-penetrating enough for deep tissue) Limited knowledge of radiation biology Single treatments not as effective as more fractions. Toxicity (acute and delayed) to normal tissues not appreciated. Limited knowledge of radiation physics Usually treated with a direct single beam of radiation. No planning for multiple beams to cover the tumor. Continued…..

Limited imaging ability Unable to adequately define the target to be treated. Surface anatomy often used to locate “tumor” -> larger treatment volumes required to ensure that tumor was treated. Unable to ensure that what was defined was actually being treated. Limited knowledge of cancer behaviour.

Early advancements Focused on increasing energy. As energies increased to 500 kV, deep-seated tumors were being treated.

Cobalt Changed The Game

60Co A significant increase in beam energy: 1.17 and 1.33 MV. -> allowed for deeper penetration with less skin damage

Linear Accelerators

Compared to 60 Co: Allowed for higher energies 4-25+ MV Deeper tumors could be treated safely without damaging the skin Allowed quicker treatment times

Progress Advances in imaging Advances in computers Advances in radiation treatment equipment.

Advances In Imaging CT / MRI IGRT

Volume Definition - Prostate bed - Pelvic Lymph Nodes Consensus statements for defining volumes for: - Prostate bed - Pelvic Lymph Nodes

Advances in Imaging

Advances in Computers Originally all calculations were done by hand.

Made plans with more than 2 beams cumbersome. Calculations for odd shapes were difficult to account for.

NOW Computers are capable of doing millions of calculations per second Allows for newer technologies to delivered reliably and accurately

Process of Radiation Planning CT simulation outlines the prostate, bladder, rectum Planning coming up with a plan to give the proper dose to the prostate without giving too much to the normal tissues. Treatment daily (Monday-Friday) for 35 – 39 days.

CT simulation CT scan with full bladder, empty rectum

Planning Will review progress later. Planning – adds a margin around the prostate to allow for motion due to bladder or rectal filling.

Treatment

Advances in Radiation Equipment IMRT VMAT IGRT Cyberknife

IMRT Intensity Modulated Radiation Therapy Focuses radiation more tightly on the prostate. Need to be able to identify the prostate before giving the radiation dose Gold seeds Daily CT scan Daily ultrasound localization

Gold seeds Gold – doesn’t react with body; dense so can be seen on treatment. Put in with transrectal ultrasound (like the biopsy in reverse) 23 Kt gold – small (don’t need to mention in the will)

A Look AT Progress:

Old Technique – 4 field Ant old old

4 Field Old r lat

4 Field Old 4 field ant volumes

4 field Lat volumes

4 field – less old ant

4 field less old R lat

Distribution 4 field old old

Distribution 4 field less old

DVH – old vs less old

Distribution – 3D conformal

DVH – less old vs 3D CRT

Distribution IMRT With beams

Distribution IMRT No beams

DVH – 3D CRT vs IMRT

Field IMRT

Advances IMRT VMAT Cyberknife

VMAT Volumetric-Modulated Arc Therapy Treatment with one or more arcs. While rotating: Radiation on continuously, but Can change shape of area being treated Can change output (amount of radiation) Can change speed of rotation.

VMAT Video

Cyberknife video

Future Hypofractionation with cyberknife or linear accelerator RTOG trial: 5 versus 12 fractions

Radionuclides 89St 153Sm 223Ra

89St β emitter T/2 50.5 days Range ~8 mm Energy 1.463 MeV Has been shown to be useful in men with castrate resistant prostate cancer with multiple bone metastases. Was used more previously before docetaxel chemotherapy.

153Sm β and γ emitter β 640, 710, and 840 keV γ 103 keV T/2 46.3 days Range 0.5 mm average, 3.0 mm maximum Less marrow effects than 89St

223Ra α emitter T/2 11.43 days Energy – max 27.7 MeV, average 6.94 Mev Range ~1 mm tested in 1 study of men with castrate resistant disease. The median time to progression was 26 weeks with 223Ra versus 8 weeks for placebo. Median survival was 41% longer (65.3 weeks versus 46.4 weeks). further study required

Adjuvant therapy 1 Hormone treatments Abiaterone MDV3100 TAK700 2 Growth Inhibitors EGFR inhibitors PIK3 inhibitors Antisense oligonucleotides (heat shock protein) 3 Immunotherapy Sipucel T treatment

Conclusions Not all prostate cancers are created equal need to know PSA, Gleason score, T-stage to determine risk category. Radiation therapy has a role in the treatment of all risk categories of prostate cancer.

Conformal radiation (IMRT / VMAT) is the mainstay of treatment for men with prostate cancer. IGRT is used in both of these methods. Cyberknife (stereotactic body radio-surgery) is being explored as a potential treatment option.

Outcomes of treatment are similar with radiation and surgery. Brings us back full circle.